EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to three new employees under NASDAQ Listing Rule 5635(c)(4).

Rhea-AI Summary

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to three new employees under NASDAQ Listing Rule 5635(c)(4). The awards cover up to 39,700 shares of common stock, granted June 15, 2026, with a ten-year term and exercise price of 12.08 per share.

Options vest over four years, with 25% after one year and the remainder in equal monthly installments over three years, subject to continued employment.

Argus Jun 16 session

+6.62% close to close Open Argus

Details

News Market Reaction – EYPT

In the Jun 16 session, EYPT gained 6.62%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.6% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.6% in the session following this news. A strong positive reaction aligns with the view that this announcement is administratively routine and non-dilutive, as it involves 39,700 shares of options granted to three new employees at $12.08. Historically, EyePoint’s stock showed mixed responses to similar corporate updates, with some inducement and governance items coinciding with modest declines. Any sharp upside move could therefore reflect broader positioning or sentiment shifts rather than the mechanics of this specific grant.

Key Figures

Inducement option shares: 39,700 shares Employees granted: 3 employees Option exercise price: $12.08 per share +3 more

Inducement option shares

39,700 shares

Non-statutory stock options for three new employees

Employees granted

3 employees

Recipients of inducement stock option awards

Option exercise price

$12.08 per share

Closing price on June 15, 2026

Option term

10 years

Duration of inducement stock option awards

Vesting period

4 years

Time over which options vest for new employees

Initial vesting tranche

25% at 1 year

First anniversary of each employee’s grant date

Historical Context

5 past events · Latest: May 19

5 events

1. May 19

   Investor conferences

   24h Move

   +1.0%

   Announced management participation in three upcoming ophthalmology and healthcare conferences.

2. May 18

   Inducement grants

   24h Move

   -5.3%

   Granted stock options to new employees under NASDAQ Rule 5635(c)(4).

3. May 14

   Clinical trial update

   24h Move

   -1.4%

   Third positive DSMC recommendation for Phase 3 DURAVYU wet AMD trials to continue unchanged.

4. May 06

   Earnings results

   24h Move

   -2.9%

   Reported Q1 2026 results with low revenue, high operating expenses, and a larger net loss.

5. Apr 29

   Earnings date notice

   24h Move

   -4.5%

   Announced timing and webcast details for upcoming Q1 2026 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-statutory stock options financial

"the Company granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"as inducement awards ... in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 39,700 shares of EyePoint common stock to three new employees. The stock options were granted on June 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of 12.08 per share, the closing price of EyePoint’s common stock on June 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com

FAQ

What inducement stock option grants did EyePoint (Nasdaq:EYPT) announce on June 16, 2026?

EyePoint announced non-statutory stock option grants covering up to 39,700 shares for three new employees. According to EyePoint, these inducement awards were made outside the 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4), with grants dated June 15, 2026.

What is the exercise price and term of the new EyePoint (EYPT) inducement stock options?

The inducement stock options have an exercise price of 12.08 per share and a ten-year term. According to EyePoint, the price equals the closing price of its common stock on June 15, 2026, the date the options were granted to new employees.

How do the EyePoint (EYPT) inducement stock options vest for new employees?

The inducement options vest over four years, starting one year after the grant date. According to EyePoint, 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the next three years, subject to continued employment.

How many shares are covered by EyePoint’s June 2026 inducement stock option awards?

EyePoint’s June 2026 inducement stock option awards cover up to an aggregate of 39,700 common shares. According to EyePoint, these options were granted to three new employees as a material inducement to joining the company, in line with NASDAQ Listing Rule 5635(c)(4).

Are EyePoint’s June 2026 inducement stock options part of the 2023 Long-Term Incentive Plan?

No, the June 2026 inducement stock options were granted outside EyePoint’s 2023 Long-Term Incentive Plan. According to EyePoint, the awards were specifically structured under NASDAQ Listing Rule 5635(c)(4) as material inducements for three new employees to enter employment.

Who approved the June 15, 2026 EyePoint (EYPT) inducement stock option grants?

The June 15, 2026 inducement stock option grants were approved by EyePoint’s Compensation Committee. According to EyePoint, the committee authorized options for three new employees as material inducement awards under NASDAQ Listing Rule 5635(c)(4), with specified vesting and exercise terms.